Teriparatide Approved in Canada for Steroid-Induced Osteoporosis
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Teriparatide Approved in Canada for Steroid-Induced Osteoporosis

TORONTO -- August 21, 2008 -- Teriparatide (rDNA origin [Forteo]) injection] has been approved by Health Canada for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women who are at high risk for bone fracture.

The approval of teriparatide is based on a 36-month, double-blind, active comparator-controlled trial published in the New England Journal of Medicine.

The study found that at 18 months of therapy, teriparatide significantly increased lumbar spine bone mineral density (BMD) from baseline (7.2%) compared with alendronate sodium (Fosamax [3.4%]).

This new indication provides patients with a new treatment option to reduce their risk of bone fracture and bone loss related to glucocorticoid therapy.

SOURCE: Eli Lilly Canada Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities